Latest Insider Transactions at Spero Therapeutics, Inc. (SPRO)
This section provides a real-time view of insider transactions for Spero Therapeutics, Inc. (SPRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Spero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Spero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2023
|
Timothy Keutzer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
265,957
+44.59%
|
-
|
|
Feb 01
2023
|
Ankit Mahadevia |
BUY
Grant, award, or other acquisition
|
Direct |
531,914
+39.64%
|
-
|
|
Sep 22
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,901,796
-19.65%
|
$3,803,592
$2.25 P/Share
|
|
Sep 15
2022
|
Frank E Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
Kathleen Tregoning |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
Patrick V.J.J. Vink |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
John C Pottage Jr |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
Scott Thomas Jackson |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Sep 15
2022
|
Milind Deshpande |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.29%
|
-
|
|
Sep 12
2022
|
Kamal Hamed Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
210,000
+50.0%
|
-
|
|
Aug 29
2022
|
Sath Shukla CEO & President |
SELL
Open market or private sale
|
Direct |
6,017
-9.69%
|
$0
$0.89 P/Share
|
|
Apr 26
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
39,727
+0.74%
|
$198,635
$5.24 P/Share
|
|
Mar 30
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.47%
|
$400,000
$8.79 P/Share
|
|
Mar 14
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
23,708
+0.23%
|
$165,956
$7.63 P/Share
|
|
Feb 28
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
44,833
+0.43%
|
$403,497
$9.53 P/Share
|
|
Feb 18
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,828
+0.29%
|
$133,452
$9.24 P/Share
|
|
Feb 01
2022
|
Tamara L Joseph Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,014
+37.98%
|
-
|
|
Feb 01
2022
|
Timothy Keutzer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,014
+37.05%
|
-
|
|
Feb 01
2022
|
Ankit Mahadevia |
BUY
Grant, award, or other acquisition
|
Direct |
134,168
+32.54%
|
-
|
|
Feb 01
2022
|
Cristina Larkin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,014
+37.42%
|
-
|
|
Feb 01
2022
|
Sath Shukla CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
38,014
+37.98%
|
-
|
|
Feb 01
2022
|
David A. Melnick Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,014
+37.98%
|
-
|
|
Jan 31
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,000
+2.37%
|
$1,375,000
$11.59 P/Share
|
|
Jan 24
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,599
+0.03%
|
$15,990
$10.89 P/Share
|
|
Jan 18
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,488
+0.96%
|
$581,856
$12.41 P/Share
|
|
Jan 10
2022
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,867
+0.18%
|
$106,404
$12.93 P/Share
|
|
Dec 31
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,000
+2.46%
|
$1,875,000
$15.75 P/Share
|
|
Dec 30
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.02%
|
$750,000
$15.77 P/Share
|
|
Dec 29
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
75,493
+1.55%
|
$1,056,902
$14.64 P/Share
|
|
Dec 27
2021
|
Ankit Mahadevia |
SELL
Open market or private sale
|
Direct |
8,000
-5.26%
|
$112,000
$14.58 P/Share
|
|
Dec 27
2021
|
Ankit Mahadevia |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+5.0%
|
$40,000
$5.9 P/Share
|
|
Oct 29
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+3.08%
|
$2,550,000
$17.53 P/Share
|
|
Sep 30
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
134,543
+2.86%
|
$2,421,774
$18.65 P/Share
|
|
Sep 14
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,156
+0.05%
|
$38,808
$18.49 P/Share
|
|
Sep 13
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
44,210
+0.99%
|
$795,780
$18.56 P/Share
|
|
Sep 09
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,749
+0.56%
|
$445,482
$18.5 P/Share
|
|
Aug 31
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,645
+1.1%
|
$875,610
$18.93 P/Share
|
|
Aug 30
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
44,042
+1.01%
|
$748,714
$17.87 P/Share
|
|
Aug 27
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
13,957
+0.33%
|
$223,312
$16.88 P/Share
|
|
Aug 26
2021
|
Sath Shukla CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+50.0%
|
-
|
|
Aug 26
2021
|
Timothy Keutzer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+47.53%
|
-
|
|
Aug 26
2021
|
Tamara L Joseph Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+50.0%
|
-
|
|
Aug 26
2021
|
Cristina Larkin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+48.49%
|
-
|
|
Aug 26
2021
|
Ankit Mahadevia |
BUY
Grant, award, or other acquisition
|
Direct |
78,219
+35.19%
|
-
|
|
Aug 26
2021
|
David A. Melnick Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,067
+50.0%
|
-
|
|
Aug 26
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,982
+0.54%
|
$367,712
$16.55 P/Share
|
|
Aug 24
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,170
+0.94%
|
$642,720
$16.28 P/Share
|
|
Aug 23
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
137,835
+3.19%
|
$2,205,360
$16.33 P/Share
|
|
Aug 20
2021
|
Aquilo Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
221,190
+5.18%
|
$3,096,660
$14.86 P/Share
|